These results highlighted the ability of Lnc-THOR in promoting NSCLC progression by associating with IGF2BP1, suggesting that Lnc-THOR represents a promising and novel therapeutic target of NSCLC. This evidence concerns the gene IGF2BP1 and non-small cell lung carcinoma.